Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.53 |
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | SNCA | P37840 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1122565 | 1.00 | NFE2L2 (0.56) | NFE2L2PPARGTRPA1TRPM8LMNA | |
| SCHEMBL1122555 | 0.86 | RELA (0.46) | NFE2L2PPARGTRPM8LMNAALDH1A1 | |
| SCHEMBL7902110 | 0.75 | NFE2L2 (0.68) | NFE2L2PPARGTRPA1LMNAALDH1A1 | |
| SCHEMBL7902113 | 0.75 | NFE2L2 (0.68) | NFE2L2PPARGTRPA1LMNAALDH1A1 | |
| SCHEMBL8001633 | 0.74 | NFE2L2 (0.50) | NFE2L2PPARGTRPA1LMNAALDH1A1 | |
| SCHEMBL22735359 | 0.74 | PPARG (0.91) | NFE2L2PPARGTRPA1LMNAALDH1A1 | |
| SCHEMBL22735360 | 0.74 | PPARG (0.91) | NFE2L2PPARGTRPA1LMNAALDH1A1 | |
| SCHEMBL29259144 | 0.73 | NFE2L2 (0.60) | NFE2L2PPARGTRPA1LMNAALDH1A1 | |
| SCHEMBL7267305 | 0.73 | PGR (0.82) | LMNAALDH1A1PGRL3MBTL1MAPT | |
| SCHEMBL21616535 | 0.73 | TRPA1 (0.56) | NFE2L2PPARGTRPA1TRPM8LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379508-B9 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2011-02-09 | — | — | EP | claimed |
| EP-1379508-B1 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2010-09-01 | — | — | EP | claimed |
| EP-1379508-A4 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2005-12-28 | — | — | EP | claimed |
| EP-1379508-A2 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2004-01-14 | — | — | EP | claimed |
| US-6646009-B2 | Use against proliferative disorders including cancer, and as a radioprotective compound for normal cells from ionizing radiation | Temple University — Of Commonwealth System of Higher Education | 2003-11-11 | — | — | US | claimed |
| US-20020165412-A1 | N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof | ONCONOVA THERAPEUTICS, INC. | 2002-11-07 | — | — | US | claimed |
| WO-2002067865-A2 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2002-09-06 | — | — | WO | claimed |
| EP-1379508-B9 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2011-02-09 | — | — | EP | disclosed |
| EP-1379508-B1 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-1379508-A4 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | UNIV TEMPLE (US) | 2005-12-28 | — | — | EP | disclosed |
| EP-1379508-A2 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | Temple University of the Commonwealth System of Higher Education (US) | 2004-01-14 | — | — | EP | disclosed |
| US-6646009-B2 | Use against proliferative disorders including cancer, and as a radioprotective compound for normal cells from ionizing radiation | Temple University — Of Commonwealth System of Higher Education | 2003-11-11 | — | — | US | disclosed |
| US-20020165412-A1 | N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof | ONCONOVA THERAPEUTICS, INC. | 2002-11-07 | — | — | US | disclosed |
| WO-2002067865-A2 | N-(ARYL)-2-ARYLETHENESULFONAMIDES AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165412-A1 | N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof | HCCS, NAT1, ARSA | NFE2L2 16/4885PPARG 375/4885TRPA1 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.